Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEFOX: D,L-methadone plus mFOLFOX6 in advanced colorectal cancer
2024-519509-37-00Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methadone in colorectal cancer (CRC) (2 arms), sponsored by AIO-Studien. Primary endpoints: Phase I toxicity profile and MTD/RPTD of D,L-methadone with mFOLFOX6 and Disease control rate at 12 weeks (Phase II, ITT). Started Nov 2024; status: completed.
02
Drugs
methadone
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-519509-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519509-37-00.